484 related articles for article (PubMed ID: 18847313)
21. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
22. HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.
Forristal CE; Nowlan B; Jacobsen RN; Barbier V; Walkinshaw G; Walkley CR; Winkler IG; Levesque JP
Leukemia; 2015 Jun; 29(6):1366-78. PubMed ID: 25578474
[TBL] [Abstract][Full Text] [Related]
23. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.
Yannaki E; Karponi G; Zervou F; Constantinou V; Bouinta A; Tachynopoulou V; Kotta K; Jonlin E; Papayannopoulou T; Anagnostopoulos A; Stamatoyannopoulos G
Hum Gene Ther; 2013 Oct; 24(10):852-60. PubMed ID: 24001178
[TBL] [Abstract][Full Text] [Related]
25. Can every patient be mobilized?
DiPersio JF
Best Pract Res Clin Haematol; 2010 Dec; 23(4):519-23. PubMed ID: 21130416
[TBL] [Abstract][Full Text] [Related]
26. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice.
Juarez JG; Harun N; Thien M; Welschinger R; Baraz R; Pena AD; Pitson SM; Rettig M; DiPersio JF; Bradstock KF; Bendall LJ
Blood; 2012 Jan; 119(3):707-16. PubMed ID: 22049516
[TBL] [Abstract][Full Text] [Related]
27. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
[TBL] [Abstract][Full Text] [Related]
28. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.
Liles WC; Broxmeyer HE; Rodger E; Wood B; Hübel K; Cooper S; Hangoc G; Bridger GJ; Henson GW; Calandra G; Dale DC
Blood; 2003 Oct; 102(8):2728-30. PubMed ID: 12855591
[TBL] [Abstract][Full Text] [Related]
29. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
[TBL] [Abstract][Full Text] [Related]
30. New agents for mobilizing peripheral blood stem cells.
Greinix HT; Worel N
Transfus Apher Sci; 2009 Aug; 41(1):67-71. PubMed ID: 19615944
[TBL] [Abstract][Full Text] [Related]
31. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.
Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A
Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941
[TBL] [Abstract][Full Text] [Related]
32. Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.
Cashen AF
Drugs Today (Barc); 2009 Jul; 45(7):497-505. PubMed ID: 19834627
[TBL] [Abstract][Full Text] [Related]
33. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent.
Cashen AF; Nervi B; DiPersio J
Future Oncol; 2007 Feb; 3(1):19-27. PubMed ID: 17280498
[TBL] [Abstract][Full Text] [Related]
34. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.
Flomenberg N; DiPersio J; Calandra G
Acta Haematol; 2005; 114(4):198-205. PubMed ID: 16269859
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 and mobilization of hematopoietic precursors.
Rettig MP; Ramirez P; Nervi B; DiPersio JF
Methods Enzymol; 2009; 460():57-90. PubMed ID: 19446720
[TBL] [Abstract][Full Text] [Related]
36. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
Broxmeyer HE; Orschell CM; Clapp DW; Hangoc G; Cooper S; Plett PA; Liles WC; Li X; Graham-Evans B; Campbell TB; Calandra G; Bridger G; Dale DC; Srour EF
J Exp Med; 2005 Apr; 201(8):1307-18. PubMed ID: 15837815
[TBL] [Abstract][Full Text] [Related]
37. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
[TBL] [Abstract][Full Text] [Related]
38. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience.
Fowler CJ; Dunn A; Hayes-Lattin B; Hansen K; Hansen L; Lanier K; Nelson V; Kovacsovics T; Leis J; Calandra G; Maziarz RT
Bone Marrow Transplant; 2009 Jun; 43(12):909-17. PubMed ID: 19182831
[TBL] [Abstract][Full Text] [Related]
39. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
40. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.
Devine SM; Vij R; Rettig M; Todt L; McGlauchlen K; Fisher N; Devine H; Link DC; Calandra G; Bridger G; Westervelt P; Dipersio JF
Blood; 2008 Aug; 112(4):990-8. PubMed ID: 18426988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
